India is to take action against six drugmakers after the National Pharmaceutical Pricing Authority (NPPA) found that they were offering products which had not been approved or whose prices exceeded voluntarily-agreed limits.
The NPPA’s investigations found 39 unapproved formulations and 58 overpriced products among the list of 886 medicines for which 11 drugmakers had voluntarily agreed to reduce their prices, Chemicals and Fertilisers Minister Ram Vilas Paswan has announced.
Of the unapproved products, 33 were manufactured by Cadila Healthcare, while two each belonged to Alembic (for Bivinal Syrup) and Medley Pharma (Ultiseng and Vitaseng) and one each for Lupin (Lupiqyl Gel) and Wockhardt (Miltixocx). 54 of the overpriced products were made by Cadila Healthcare and the remaining four belonged to Emcure.
The products involved range from antibiotics, cough syrups and pain killers to anti-infectives and hypertension treatments, Minister Paswan noted. By Lynne Taylor
